Alvotech is a vertically integrated biotechnology company focused on the development and manufacture of biosimilar medicines for the global market. Founded in 2013, the company operates a comprehensive platform that covers the entire value chain, from identifying therapeutic areas and target product candidates through research and development, leveraging host cell lines and cell-culture processes, to cGMP manufacturing, clinical testing, and regulatory approvals. Alvotech holds five approved biosimilar products, including AVT02 (biosimilar to Humira), AVT04 (biosimilar to Stelara), AVT05 (biosimilar to Simponi), AVT06 (biosimilar to Eylea), and AVT03 (biosimilar to Prolia and Xgeva), which are approved in major markets such as the United States, Canada, the United Kingdom, the European Economic Area, and Japan. The company’s pipeline targets serious diseases in autoimmune, eye, respiratory, and hematological areas, as well as cancer. Alvotech commercializes its products through strategic partnerships with pharmaceutical companies, licensing its intellectual property in exchange for development and commercialization milestone payments and royalties. The company maintains a manufacturing agreement with LOTTE Biologics to increase global supply and has received FDA approval for additional U.S. manufacturing capacity for its biosimilar to Humira, marketed as SIMLANDI.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage alvotech.com
Sector Healthcare IR page alvotech.com
Tags
biosimilars, biologics, autoimmune diseases, oncology, ophthalmology, hematology, respiratory diseases, cgmp manufacturing, cell line development, clinical development, regulatory affairs, pharmaceutical partnerships, AVT02, AVT04, AVT05, AVT06, AVT03, AVT80, SIMLANDI, Humira, Stelara, Simponi, Eylea, Prolia, Xgeva, Entyvio, LOTTE Biologics, Alvotech hf., Alvotech USA Inc.
Press page alvotech.com/newsroom

Metrics

Valuation  
Market cap $ 2.07B
Market cap (USD) $ 2.07B
P/E -9.51
PEG —
P/BV -10.81
P/S 4.21
P/OCF -10.42
P/FCF -7.92
Dividend yield —
Turnover / mcap —
Returns  
ROE -9.8%
ROI 2.8%
ROIC 3.9%
Profit margin 4.8%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 58
Quality score -23.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 USD FY 2024 USD FY 2023 USD FY 2022 USD FY 2021 USD
Revenue 586.32M 489.68M 91.43M 83.02M 36.77M
Net profit 27.91M -231.86M -551.73M -513.58M -101.5M

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

REYKJAVIK, Iceland, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financial results for the nine months to September 30, 2026, and provided a business update.

Supplemental information, including the management presentation providing additional details and a business update, is available on our website: https://alvotech.com/financials.1

Financial Highlights for the Nine Months to September 30, 20262

Adjusted total revenue2 was $323.4 million compared to $420.0 million in the same period last year.

Gross Margin was 54% compared to 59% in the same period last year.

Adjusted EBITDA2 was $78.3 million compared to $68.0 million in the same period last year.

Reported cash balance at the end of the period was $61.5 million compared to $172.4 million on December 31, 2025.

Company Announcement

28 October 2026

REYKJAVIK, ICELAND (October 28, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its financial results for the nine months and third quarter ended September 30, 2026 on Wednesday, November 11, 2026, after the U.S. market close.

The Company will also host a webcast with a live Q&A on Thursday, November 12, 2026, at 08:00 ET (13:00 GMT, 14:00 CET).

Slides and other materials will be made available on alvotech.com/financials before the earnings call.

Company Announcement

20 October 2026

Enhanced process increases manufacturing productivity and frees up capacity to support growing demand across Alvotech’s biosimilars portfolio

REYKJAVIK, Iceland and LONDON, UK (October 20, 2026) - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced
that the U.S. Food and Drug Administration (FDA) has approved a new manufacturing process for SIMLANDI® (adalimumab-ryvk), Alvotech’s biosimilar to Humira® (adalimumab).

The FDA approval allows Alvotech to introduce Process 2.0 for the manufacture of adalimumab drug substance in its DSM2 manufacturing suite in Reykjavik, Iceland. The new process more than doubles drug substance output per batch without changing the upstream manufacturing scale.

The improvement was achieved through targeted process development, effective process transfer and successful process validation, with demonstrated comparability to the previously approved process, maintaining product quality, safety and efficacy.

“More than doubling drug substance output per batch while maintaining product quality is a significant achievement that reflects the expertise of our process development and manufacturing teams,” said Joseph McClellan, Chief Operating Officer of Alvotech. “The new process allows us to manufacture the same quantity of drug substance in fewer batches, freeing up capacity to support other products in our portfolio, making better use of our existing infrastructure and giving us greater flexibility to respond to growing demand. Together with the recent FDA approval of additional manufacturing capacity, this demonstrates the strength of our operations in Reykjavik and reinforces our ability to deliver reliable supply to our commercial partners as demand for our biosimilars continues to grow.”

Prompts

Alvotech (ticker ALVO), listed in United States.

Company History

Date Change Detail
Jan 18, 2022 Renamed ALVOTECH LUX HOLDINGS S.A.S. → ALVOTECH

ETFs Holding Alvotech

ETF Weight in ETF Shares Market value As of
TIER 0.02% 1,613 $ 6,645.56 Jul 31, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
ALVO-SDB Common share — SE nordic — —
ALVO canonical Common share — US nasdaq 5.80 USD 2026-09-30
ALVOW Warrant — US nasdaq 0.35 USD 2026-09-30